MedTrace Logo

Evaluating Immune Response to COVID-19 Vaccines in Patients With Cancer, Transplant or Cellular Therapy Recipients

NCT05164016 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 21

Last updated 2026-04-15

No results posted yet for this study

Summary

This study is being done because the investigators would like to learn more about how well the COVID-19 vaccine works in participants with cancer or those who have received a transplant or cellular therapy.

Primary Objective

Assess the immunogenicity to COVID-19 vaccination in patients with cancer and/or transplant and cellular therapy (TCT) recipients.

Secondary Objectives

* Evaluate the antibodies response to COVID-19 vaccination in immunocompromised patients.
* Evaluate the T cell response to COVID-19 vaccination in immunocompromised patients.

Exploratory Objectives

* Assess incidence and severity of COVID-19 infections by 6 months following immunization with a SARS CoV-2 vaccine.
* Assess the durability immune response to COVID-19 vaccination.
* Assess the immunogenicity of COVID-19 vaccination in immunocompetent children and adolescents without cancer and have not undergone transplant or received cellular therapy.

Conditions

  • Cancer
  • Hematopoietic System--Cancer
  • Transplant-Related Cancer
  • Solid Tumor Malignancy
  • Hematologic Malignancy
  • Solid Organ Transplant
  • Hematopoietic Cell Transplant
  • Cellular Therapy

Sponsors & Collaborators

Principal Investigators

  • Diego Hijano, MD · St. Jude Children's Research Hospital

Eligibility

Max Age
24 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-29
Primary Completion
2025-05-01
Completion
2026-04-09

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05164016 on ClinicalTrials.gov